William Biggs, MD
Endocrinology, Diabetes & Metabolism · Amarillo, TXNPI 1033280862
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (39.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 40 manufacturers reported payments, led by Roche Diabetes Care, Inc. at 40.6% of the total. Reporting peaked in 2019 at $29,896 and has fallen 88.1% since, to $3,560 in 2025.
Across 569 payments — averaging $77.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Diabetes Care, Inc.$18K
- Novo Nordisk AS$11K
- Novo Nordisk$2K
- Amgen$2K
- Insulet Corporation$2K
- Tandem Diabetes Care, Inc.$2K
- plus $8K from 34 others
Across 4,277 payments — averaging $513.27 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novo Nordisk AS$1.6M
- Boehringer Ingelheim$446K
- Dexcom, Inc.$62K
- Roche Diabetes Care, Inc.$37K
- Boehringer Ingelheim International GmbH$22K
What the payments were for
- Consulting fees$17,53440%
- Speaking & faculty fees$1,5503%
- Travel & lodging$12,99829%
- Food & beverage$12,14527%
- Education$610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DC ACCU-CHEK Diabetes Management Solutions, Cables, Software, Kits and Accessori$17,973
- Ozempic$9,447
- Omnipod$1,615
- t:slim X2 insulin pump$1,550
- Tresiba$1,013
- EVENITY$696
- Prolia$337
- t:slim X2 Insulin Pump with Control-IQ$139
- TZIELD$134
- XGEVA$125
- TEPEZZA$113
- DEXCOM G6 TRANSMITTER$110
How this compares
$44,288 in reported general payments places this provider in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
See all endocrinology, diabetes & metabolism providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 272 | $461,155 |
| Tresiba Flextouch U-200Insulin Degludec | 129 | $241,236 |
| Tresiba Flextouch U-100Insulin Degludec | 164 | $128,608 |
| JardianceEmpagliflozin | 110 | $125,144 |
| FarxigaDapagliflozin Propanediol | 93 | $83,520 |
| Humalog Kwikpen U-200Insulin Lispro | 25 | $74,700 |
| MounjaroTirzepatide | 39 | $45,937 |
| TrulicityDulaglutide | 27 | $34,384 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 19 | $31,821 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 53 | $28,963 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 141 | $24,925 |
| JanuviaSitagliptin Phosphate | 16 | $23,854 |
| RybelsusSemaglutide | 12 | $20,269 |
| Novolog FlexpenInsulin Aspart | 66 | $19,918 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $19,661 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $2,052 | $492,551328 claims |
| Boehringer IngelheimJardiance | $749 | $125,144110 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $637 | $94,116122 claims |
| AstraZenecaFarxiga | $926 | $83,52093 claims |
| MerckJanuvia | $68 | $23,85416 claims |
| Sanofi-aventis U.S. LLCLantus | $634 | $8,56324 claims |
| AbbVieSynthroid | $562 | $4,12266 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 658 endocrinology, diabetes & metabolism providers in Texas.
Other endocrinology, diabetes & metabolism in Amarillo
- Kenny BrantleyAmarillo$128K
- Lance SloanLufkin$1.7M
- Pablo MoraDallas$1.3M
- Robert HoodBeaumont$1.3M
- Eduardo LunaEdinburg$1.3M
- Steve FordanDallas$1.2M
- Rosemarie LajaraPlano$1.2M
- Saleemah FahmiDallas$1.2M
- Julio RosenstockDallas$1.2M
- Rocio HarbisonHouston$989K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.